免費咨詢(xún)熱線(xiàn)：
15522676233
達克替尼 Dacomitinib Dacomitinib, also known as PF-299 and PF-00299804 ; or PF299804, is an orally bioavailable, highly selective, second-generation small-molecule inhibitor
更新時(shí)間：2023-07-12
廠(chǎng)商性質(zhì)：代理商
吡昔替尼 Pexidartinib Pexidartinib, also know as PLX-3397, is a CSF1R inhibitor with IC50 of 20 nM in development by Plexxikon for the treatment of tenosynovial giant cell tumors.
更新時(shí)間：2023-07-12
廠(chǎng)商性質(zhì)：代理商
瑞博西尼 Ribociclib Ribociclib Free Base, also known as LEE011, is an orally available cyclin-dependent kinase (CDK) inhibitor targeting cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway,
更新時(shí)間：2023-07-12
廠(chǎng)商性質(zhì)：代理商
帕布昔利布 Palbociclib Palbociclib, also known as PD-0332991, is an orally available cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity.
更新時(shí)間：2023-07-12
廠(chǎng)商性質(zhì)：代理商
?，斘髂?Abemaciclib Also known as LY2835219, is orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antine
更新時(shí)間：2023-07-12
廠(chǎng)商性質(zhì)：代理商
微信掃一掃
